Interview: Silence Therapeutics’ Chair On Why Keeping Quiet Has Done The Biotech No Favors
Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.
You may also be interested in...
Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.
Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.
The RNAi developer is preparing for Phase I clinical trials of three product candidates coming out of a next-generation technology platform. After a decade of RNAi development, CEO Douglas Fambrough says Dicerna is ready to earn back its place as a valuable biotech.